Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Weak
Earnings
Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.8.6151.0992
Address
6 Verdun Street Harry Perkins Institute Nedlands, Western Australia (WA) 6009
Description
PYC Therapeutics Ltd. is a drug-development company, which provides a new generation of RNA therapeutics to meet unmet need in disease. It develops intracellular biological therapeutics including its own preclinical oncology payloads, using its proprietary cell Functional Penetrating Phylomers. The company was founded by Richmond Miles Hopkins and Paul Michael Watt on October 9, 2001, and is headquartered in Nedlands, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.05 - 0.14
Trade Value (12mth)
AU$58,098.00
1 week
-10.71%
1 month
25%
YTD
26.49%
1 year
125.87%
All time high
0.65
EPS 3 yr Growth
65.50%
EBITDA Margin
N/A
Operating Cashflow
-$39m
Free Cash Flow Return
-70.70%
ROIC
-69.10%
Interest Coverage
-1,206.20
Quick Ratio
9.40
Shares on Issue (Fully Dilluted)
4084m
HALO Sector
Healthcare
Next Company Report Date
02-Sep-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
30 August 24 |
Q3 2024 Investor Webinar Presentation
×
Q3 2024 Investor Webinar Presentation |
30 August 24 |
FDA Grants Rare Pediatric Disease Designation to PYC-001
×
FDA Grants Rare Pediatric Disease Designation to PYC-001 |
29 August 24 |
Appendix 4E and Audited Financial Statements
×
Appendix 4E and Audited Financial Statements |
22 August 24 |
Q3 Investor Webinar 30 August 2024
×
Q3 Investor Webinar 30 August 2024 |
15 August 24 |
PYC to Start Human Trials in Second Blinding Eye Disease
×
PYC to Start Human Trials in Second Blinding Eye Disease |
13 August 24 |
Canaccord Genuity Growth Conference Presentation
×
Canaccord Genuity Growth Conference Presentation |
12 August 24 |
Visual Improvement in Multiple RP11 Patients
×
Visual Improvement in Multiple RP11 Patients |
05 August 24 |
RP11 Clinical Trial Update
×
RP11 Clinical Trial Update |
05 August 24 |
RP11 Clinical Trial Update - Amended
×
RP11 Clinical Trial Update - Amended |
02 August 24 |
Completion of Small Shareholding Sale Facility
×
Completion of Small Shareholding Sale Facility |
23 July 24 |
Extension of RP11 Single Dose Study Into Multiple Dose Study
×
Extension of RP11 Single Dose Study Into Multiple Dose Study |
22 July 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
17 July 24 |
Initial Dosing Completed in Cohort 1 of RP11 MAD Study
×
Initial Dosing Completed in Cohort 1 of RP11 MAD Study |
12 July 24 |
Bioshares Biotech Summit Presentation
×
Bioshares Biotech Summit Presentation |
10 July 24 |
Commencement of RP11 Multiple Dose Trial
×
Commencement of RP11 Multiple Dose Trial |
02 July 24 |
Notification regarding unquoted securities - PYC
×
Notification regarding unquoted securities - PYC |
01 July 24 |
RP11 Drug Candidate Safe and Well Tolerated
×
RP11 Drug Candidate Safe and Well Tolerated |
07 June 24 |
PMS Drug Candidate Effective In Human Brain Cells
×
PMS Drug Candidate Effective In Human Brain Cells |
24 May 24 |
Small Shareholdings Sale Facility
×
Small Shareholdings Sale Facility |
24 May 24 |
US FDA Grants Orphan Drug Designation to PYC Drug Candidate
×
US FDA Grants Orphan Drug Designation to PYC Drug Candidate |
23 May 24 |
Notification regarding unquoted securities - PYC
×
Notification regarding unquoted securities - PYC |
23 May 24 |
Issue of Options
×
Issue of Options |
17 May 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
17 May 24 |
Change in substantial holding
×
Change in substantial holding |
16 May 24 |
RP11 Clinical Trial Dosing Completed in Cohort 4
×
RP11 Clinical Trial Dosing Completed in Cohort 4 |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.